{"name":"Ajanta Pharma","slug":"ajanta-pharma","ticker":"AJANTPHARM.NS","exchange":"NSE","domain":"ajantapharma.com","description":"Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.","hq":"Mumbai, Maharashtra, India","founded":0,"employees":"","ceo":"","sector":"Specialty Generics — Dermatology / Ophthalmology / Cardiovascular","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":3259.2,"stockChange":136,"stockChangePercent":4.35,"marketCap":"$4.3B","metrics":{"revenue":569429825.6179364,"revenueGrowth":21.5,"grossMargin":78.3,"rdSpend":0,"netIncome":110275693.44,"cash":69404762.5537874,"dividendYield":1.79,"peRatio":38.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","genericName":"EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE","slug":"empagliflozin-metformin-hydrochloride","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","genericName":"EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE","slug":"empagliflozin-metformin-hydrochloride","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":569429846.3364,"revenuePeriod":"2026-03-31","revenueHistory":[{"period":"2026-03-31","value":569429846.3364},{"period":"2025-03-31","value":485390578.294},{"period":"2024-03-31","value":434585438.5066},{"period":"2023-03-31","value":387167934.6048}],"grossProfit":445812464.834,"grossProfitHistory":[{"period":"2026-03-31","value":445812464.834},{"period":"2025-03-31","value":373573531.4116},{"period":"2024-03-31","value":318115091.5298},{"period":"2023-03-31","value":270550344.5146}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":47944863.988800004,"operatingIncome":292899969.4294,"operatingIncomeHistory":[{"period":"2026-03-31","value":292899969.4294},{"period":"2025-03-31","value":244730585.7996},{"period":"2024-03-31","value":109193822.0536},{"period":"2023-03-31","value":70985800.5424}],"netIncome":110275693.44,"netIncomeHistory":[{"period":"2026-03-31","value":110275693.44},{"period":"2025-03-31","value":96114247.6186},{"period":"2024-03-31","value":85230788.5558},{"period":"2023-03-31","value":61401422.5652}],"eps":84.51,"epsHistory":[{"period":"2026-03-31","value":84.51},{"period":"2025-03-31","value":73.53},{"period":"2024-03-31","value":64.77},{"period":"2023-03-31","value":45.89}],"cash":10783208.4324,"cashHistory":[{"period":"2026-03-31","value":10783208.4324},{"period":"2025-03-31","value":18287385.8288},{"period":"2024-03-31","value":13522348.0526},{"period":"2023-03-31","value":34443401.4842}],"totalAssets":642736031.2616,"totalLiabilities":169982253.785,"totalDebt":27168965.1158,"equity":472753777.4766,"operatingCashflow":55262115.7306,"operatingCashflowHistory":[{"period":"2026-03-31","value":55262115.7306},{"period":"2025-03-31","value":120846913.5602},{"period":"2024-03-31","value":81983085.8418},{"period":"2023-03-31","value":82718257.1314}],"capex":-38132833.5384,"capexHistory":[{"period":"2026-03-31","value":-38132833.5384},{"period":"2025-03-31","value":-33199667.1008},{"period":"2024-03-31","value":-15915831.8534},{"period":"2023-03-31","value":-18221596.3526}],"freeCashflow":17129282.1922,"dividendsPaid":-36520469.2328,"buybacks":0,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":36494362.2978,"ebitda":41232248.861600004,"period":"2026-03-31","revenue":148458652.2936,"epsBasic":21.35,"netIncome":27850878.258,"rdExpense":null,"epsDiluted":21.34,"grossProfit":116628032.8642,"operatingIncome":76309526.72760001},{"sga":null,"ebit":37980369.038,"ebitda":42524020.0054,"period":"2025-12-31","revenue":143571434.0616,"epsBasic":21.91,"netIncome":28589182.3798,"rdExpense":null,"epsDiluted":21.91,"grossProfit":113677949.2092,"operatingIncome":74618841.617},{"sga":null,"ebit":35128447.4586,"ebitda":39440268.8432,"period":"2025-06-30","revenue":136032795.511,"epsBasic":20.44,"netIncome":26664579.1316,"rdExpense":null,"epsDiluted":20.43,"grossProfit":107223270.5998,"operatingIncome":71280286.7692},{"sga":null,"ebit":28767753.8152,"ebitda":32921889.312400002,"period":"2025-03-31","revenue":122223271.1734,"epsBasic":18,"netIncome":23523392.7124,"rdExpense":null,"epsDiluted":18,"grossProfit":92626361.10260001,"operatingIncome":59255432.5082},{"sga":null,"ebit":32926066.422000002,"ebitda":36682332.2298,"period":"2024-12-31","revenue":119687765.6462,"epsBasic":18.6,"netIncome":24319132.0912,"rdExpense":null,"epsDiluted":18.59,"grossProfit":92765249.9968,"operatingIncome":61317880.3732}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3259.2,"previousClose":3123.2,"fiftyTwoWeekHigh":3280,"fiftyTwoWeekLow":2329.9,"fiftyTwoWeekRange":"2329.9 - 3280.0","fiftyDayAverage":2888.63,"twoHundredDayAverage":2701.88,"beta":0.2,"enterpriseValue":4209356704.32419,"forwardPE":28.6,"priceToBook":8.99,"priceToSales":7.47,"enterpriseToRevenue":7.39,"enterpriseToEbitda":26.91,"pegRatio":0,"ebitda":156419181.92131892,"ebitdaMargin":27.5,"freeCashflow":90591.06445,"operatingCashflow":55262114.7280937,"totalDebt":27168966.118306305,"debtToEquity":5.7,"currentRatio":2.64,"returnOnAssets":14.8,"returnOnEquity":25.4,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":3299.71,"targetHighPrice":3829,"targetLowPrice":2605,"dividendRate":56,"payoutRatio":0.33,"fiveYearAvgDividendYield":0.89,"exDividendDate":1762732800,"insiderHeldPercent":66.4,"institutionHeldPercent":21.8,"sharesOutstanding":124935624,"floatShares":41971173,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":84.64,"epsForward":113.77,"revenuePerShare":436.49,"bookValue":362.4,"officers":[{"age":53,"name":"Mr. Yogesh Mannalal Agrawal M.B.A","title":"MD & Executive Director"},{"age":49,"name":"Mr. Rajesh Mannalal Agrawal M.B.A","title":"Joint MD & Director"},{"age":70,"name":"Mr. Madhusudan Bhagwandas Agrawal B.Sc","title":"Executive Vice Chairman of the Board"},{"age":62,"name":"Mr. Arvind K. Agrawal B Com, F.C.A, L.L.B","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Gaurang Chinubhai Shah","title":"Senior VP of Legal, VP of Corporate Affairs, Company Secretary & Compliance Officer"},{"age":62,"name":"Mr. H. Satish Agrawal M Pharm","title":"President of Technical & Operations"},{"age":null,"name":"Mr. Pourus  Vakil","title":"President of Sales & Marketing"},{"age":null,"name":"Mr. Thampy  Jacob","title":"Senior Vice President of HR"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.ajantapharma.com","phone":"91 22 6060 9000"}}